The aim of our study is to determine the correlation of GP96 and AR expression with other clinicopathological factors and non-SLN status in early-stage BC patients with SLN involvement, as well as their impact on 5-year overall and disease-free survival (OS and DFS, respectively). Here, AR is linked to breast cancer.